Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Erlotinib for TNBC
NCT00834678Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Apr 2009
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, erlotinib in triple-negative breast cancer (TNBC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Apr 2009; status: completed.
02
Drugs
bendamustineerlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00834678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00834678.